Mission Statement, Vision, & Core Values (2026) of Chengdu Kanghua Biological Products Co., Ltd.

Founded in 2004, Chengdu Kanghua Biological Products Co., Ltd. operates a cutting-edge biomanufacturing hub-an integrated campus of approximately 30,000 square meters in the Chengdu Economic and Technological Development Zone-housing a world-class biotechnology experimental center and GMP-certified bacterial and viral vaccine workshops; its marketed portfolio includes the widely distributed Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin and the freeze-dried Human Diploid Cell Rabies Vaccine (HDCV), and recent strategic developments culminated in a high-profile acquisition announced in July 2025 by Shanghai Healthcare M&A Fund aimed at scaling Kanghua's mature product sales, expanding a diversified vaccine pipeline, and integrating top-tier R&D and manufacturing capabilities to accelerate market penetration and public-health impact.

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) - Intro

• Established in 2004, Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) focuses on R&D, production and commercialization of biological products for infectious disease prevention.
• The company operates a 30,000-square-meter manufacturing and R&D campus located in the Chengdu Economic and Technological Development Zone, including a biotechnology experimental center and GMP-certified bacterial and viral vaccine production workshops.
• Principal commercial products include the Group ACYW135 Meningococcal Polysaccharide Vaccine - Maikexin - and a freeze-dried Human Diploid Cell Rabies Vaccine (HDCV), both widely distributed across China through provincial CDCs and public health channels.
• In July 2025 Shanghai Healthcare M&A Fund announced a strategic acquisition of Kanghua to leverage Shanghai's advanced R&D ecosystem, accelerate commercialization of mature products, and expand a diversified vaccine pipeline.

• Mission: Provide safe, effective and accessible vaccines to protect public health in China and select international markets, through rigorous quality controls and continuous innovation.
• Vision: Build an integrated vaccine ecosystem that pairs proven commercial products with best-in-class R&D to deliver a broad, sustainable portfolio addressing major infectious threats.
• Core values:
  • Scientific integrity - evidence-based R&D and compliance with GMP and regulatory standards.
  • Quality first - end-to-end quality management from seed strains to finished doses.
  • Collaboration - open partnerships with academic institutions, clinical sites and strategic investors (e.g., Shanghai Healthcare M&A Fund).
  • Accessibility - expanding distribution and production capacity to meet public health demand.

• R&D focus: optimize existing licensed products for enhanced stability and delivery; advance candidate vaccines that can leverage existing GMP lines to shorten time-to-market.
• Manufacturing upgrades: planned capacity scaling and process optimization to increase throughput while maintaining GMP compliance; integration with Shanghai-based R&D and talent to accelerate biologics development.
• Commercial pathway: leverage established distribution networks across provincial CDCs and immunization programs to accelerate sales of mature products while introducing new pipeline candidates into public and private channels.

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) - Overview

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) centers its corporate purpose on delivering safe, effective and accessible biological products to prevent infectious diseases and improve public health outcomes. The company integrates R&D, manufacturing, regulatory compliance and commercial operations to scale vaccine solutions that align with international standards and global immunization priorities.

Mission Statement

• Dedicated to the research, development, production and sales of biological products for disease prevention, with an emphasis on innovative vaccine solutions that improve public health.
• Provide high-quality vaccines meeting international safety and efficacy benchmarks through robust quality control, GMP-compliant manufacturing and regulatory transparency.
• Expand product portfolio to address a broad spectrum of infectious diseases and support global health initiatives, including endemic and epidemic threats.
• Continuously improve manufacturing processes and operational efficiency to raise product quality, lower unit costs and increase supply resilience.
• Foster strategic partnerships with research institutions, contract manufacturers, distributors and global health organizations to accelerate commercialization and market reach.
• Establish Kanghua as a leading global vaccine company contributing to the reduction and eradication of preventable diseases worldwide.

Vision

• To be recognized as a globally trusted vaccine developer and manufacturer, delivering life-saving immunizations that are accessible across emerging and developed markets.
• To lead in selected vaccine niches through scientific excellence, scalable manufacturing and partnerships that amplify public health impact.

Core Values

• Science-led innovation: Prioritize rigorous science and evidence-based development.
• Quality & Safety: Uphold uncompromising standards across R&D and manufacturing.
• Public Health Commitment: Align product strategy with population health needs.
• Collaboration: Build partnerships that accelerate access and distribution.
• Integrity & Compliance: Maintain regulatory compliance and ethical conduct.
• Sustainability: Optimize operations for long-term social and economic value.

Strategic Focus Areas & Operational Priorities

• Pipeline diversification: advance vaccines across bacterial and viral targets to broaden market and public health coverage.
• Manufacturing scale-up: invest in modular GMP facilities, process validation and automation to raise annual output capacity and reduce batch variability.
• Global registration strategy: pursue WHO prequalification and regulatory approvals in priority export markets.
• Partnerships & commercialization: license technologies, co-develop with research institutes and secure distribution agreements for expanded reach.
• R&D intensity: allocate a sustained portion of revenues to novel antigen design, adjuvants and formulation stability.

Selected Real-World Indicators

Quality, Compliance & Manufacturing Excellence

• Operate GMP-certified facilities with end-to-end quality systems covering raw materials, in-process controls and release testing.
• Adopt process improvements-automation, single-use systems and data-integrity solutions-to raise throughput and reduce contamination risk.
• Implement continuous training and capability development to align with international regulatory expectations (WHO, EMA, NMPA).

Partnerships, Commercialization & Market Reach

• Engage in strategic alliances for co-development, licensing and distribution to accelerate time-to-market and diversify revenue streams.
• Target tenders, public immunization programs and private market channels to balance uptake across domestic and international customers.
• Leverage external manufacturing and contract research organizations to supplement capacity during surge demand.

For deeper investor-focused context and shareholder activity related to Chengdu Kanghua Biological Products, see: Exploring Chengdu Kanghua Biological Products Co., Ltd. Investor Profile: Who's Buying and Why?

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) - Mission Statement

• Deliver high-quality, regulatory‑compliant vaccines to domestic and international markets.
• Invest consistently in R&D to shorten development timelines for next‑generation vaccines.
• Scale manufacturing and supply-chain resilience to meet surge demand during outbreaks.
• Collaborate with public health authorities, academic institutions, and commercial partners to broaden immunization impact.

• Global leadership: expand presence in Asia, Africa, Latin America and selected developed markets through regulatory approvals and partnerships.
• Integrated ecosystem: align commercialized vaccine portfolios with pipeline programs and contract manufacturing to maximize lifecycle value.
• Innovation culture: sustain a high proportion of technical staff and reinvest revenues into vaccine R&D and platform technologies.
• Capacity & scale: increase GMP production lines and cold‑chain logistics to improve market penetration and responsiveness.

• Commercial portfolio optimization: prioritize high‑demand, high‑margin vaccines while maintaining broad immunization coverage.
• Economies of scale: leverage increased volumes to lower unit manufacturing costs and improve gross margin profile.
• Financial discipline: balance reinvestment in capacity and R&D with prudent capital allocation to maintain liquidity and fund strategic initiatives.

• Talent development: recruit and retain skilled scientists, regulatory experts, and manufacturing professionals; establish continuous training programs.
• Quality first: adopt international GMP standards, robust quality systems, and third‑party audits to ensure regulatory readiness for global markets.
• Data‑driven decisions: use clinical, manufacturing and market data to prioritize projects and accelerate time‑to‑market.

Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ) - Vision Statement

• Integrity: Kanghua upholds the highest standards of ethical conduct, ensuring transparency and accountability in all its operations.
• Innovation: The company fosters a culture of innovation, investing in research and development to create advanced vaccine solutions.
• Quality: Kanghua is committed to producing vaccines that meet international quality standards, ensuring safety and efficacy for all users.
• Collaboration: The company values strategic partnerships and collaborations to enhance its capabilities and expand its market reach.
• Responsibility: Kanghua takes its role in public health seriously, striving to make a positive impact on global health through its products.
• Sustainability: The company is dedicated to sustainable practices in its operations, aiming to minimize environmental impact and promote long-term viability.

• Boost R&D: Target to increase R&D spend to 10-12% of revenue within 2-3 years to advance recombinant and adjuvanted vaccine candidates.
• Quality and Compliance: Continued investment in GMP facilities and third‑party certifications to meet WHO prequalification and major regulatory standards.
• Global Collaboration: Expand licensing, joint‑development and distribution agreements to increase export share from ~18% to 30%+ by 2027.
• Sustainability: Implement energy efficiency and waste reduction programs at manufacturing sites to lower greenhouse gas intensity per dose by 25% over five years.